<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577015</url>
  </required_header>
  <id_info>
    <org_study_id>184/2017</org_study_id>
    <nct_id>NCT03577015</nct_id>
  </id_info>
  <brief_title>International Prospective Registry of Disseminated Intravascular Coagulation</brief_title>
  <official_title>International Prospective Registry for the Diagnosis and Management of Disseminated Intravascular Coagulation in the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcella Muller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universit√† degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale S. Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poliambulanza Foundation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester Royal Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juntendo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: to evaluate the current diagnostic and therapeutic approaches for
      sepis-associated disseminated intravascular coagulation (DIC) in a large prospective
      registry.

      Design: prospective, multicenter, international registry. Study population: patients 18 years
      or older with severe infection to be potentially associated with DIC will be eligible for the
      study. The clinical visits and monitoring of the patients will follow local routine
      practices. No specific imaging tests or laboratory evaluations will be required and patients
      will be evaluated and treated according to local policy. All the involved centers will be
      asked to update information on included patients at 2, 4, 6, 8, 10 and 28 days after severe
      infection diagnosis.

      Study outcomes: The primary outcome of the study is the development of DIC. Secondary
      outcomes are thrombotic (arterial and venous) and bleeding events, overall mortality at 28
      days.

      Study sample, feasibility, and analysis plan: We plan to enroll a minimum of 1000 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>disseminated intravascular coagulation</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of disseminated intravascular coagulation:
International Society Thrombosis Hemostasis DIC score &gt;4 points (range 0-8 points) items scored: platelet count, prothrombin time, fibrinogen related marker, fibrinogen level
Japanese Association for Acute Medicine DIC score &gt;3 points (range 0-8)points items scored: inflammatory response, platelet count, prothrombin time, fibrinogen degradation products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disseminated intravascular coagulation</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of disseminated intravascular coagulation:
Japanese Association for Acute Medicine DIC score &gt;3 points (range 0-8)points items scored: inflammatory response, platelet count, prothrombin time, fibrinogen degradation products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>mortality rates in patient who develop or do not develop disseminated intravascular coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>venous thromboembolic events</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of symptomatic venous thromboembolic events including pulmonary embolism and deep vein thrombosis (VTE) of the upper and lower limbs, visceral VTE, and cerebral VTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolic events</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of arterial thromboembolic events including myocardial infarction, stroke, peripheral embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and clinically-relevant non-major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of major and clinically relevant non-major bleeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>critically ill patients at risk for DIC</arm_group_label>
    <description>patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients 18 years or older with a condition potentially associated with DIC, admitted to
        the intensive care unit, will be eligible for the study. The maximal time-window allowed
        between the diagnosis of the disease and inclusion in the study will be 72 hours.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission to the intensive care unit

          -  18 years or older

        AND one of the following conditions:

          -  sepsis/severe infection

          -  solid tumor

          -  hematological malignancy

          -  trauma

          -  obstetric complications

          -  acute pancreatitis

        Exclusion Criteria:

        -&lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Boraso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSPEDALE S. ANTONIO, Padova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcello Di Nisio, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chieti, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jecko Tachil, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Infirmary, Manchester, England</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierluigi Ferretti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Poliambulanza, Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshiaki Iba, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>(Juntendo University, Department of Emergency and Disaster Medicine, Tokyo, Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Squizzato, MD PhD</last_name>
    <email>alessandro.squizzato@uninsurbia.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcella Muller, MD PhD</last_name>
    <phone>+31-20-5669111</phone>
    <email>m.c.muller@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcella Muller, MD PhD</last_name>
      <email>m.c.muller@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Juffermans, MD PhD</last_name>
      <email>n.p.juffermans@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Marcella Muller</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>disseminated intravascular coagulation</keyword>
  <keyword>sepsis</keyword>
  <keyword>trauma</keyword>
  <keyword>pancreatitis</keyword>
  <keyword>malignancy</keyword>
  <keyword>obstetric complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

